Apogee Therapeutics, Inc. (APGE)
| Market Cap | 10.19B +378.2% |
| Revenue (ttm) | n/a |
| Net Income | -294.37M |
| EPS | -4.34 |
| Shares Out | 75.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 135.07 |
| Day's Range | n/a |
| 52-Week Range | 35.39 - 135.09 |
| Beta | 0.34 |
| Analysts | Hold |
| Price Target | 134.85 (-0.16%) |
| Earnings Date | Aug 10, 2026 |
About APGE
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for APGE stock is "Hold." The 12-month stock price target is $134.85, which is a decrease of -0.16% from the latest price.
News
AbbVie Completes Acquisition of Apogee Therapeutics
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is ...
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive ...
Apogee Therapeutics Earnings release: Q2 2026
Apogee Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Apogee Therapeutics Quarterly report: Q2 2026
Apogee Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on August 6, 2026, providing details for shareholder voting and corporate governance matters.
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on August 3, 2026, providing details for shareholder voting and corporate governance matters.
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon...
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on July 13, 2026, providing details for shareholder voting and corporate governance matters.
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on July 2, 2026, providing details for shareholder voting and corporate governance matters.
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
AbbVie's $11 Billion Immunology Bet
In this week's edition of InnovationRx, we look at AbbVie's new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more. To get ...
Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE
Micron (MU) is entering a new strategic partnership with Anthropic as Needham raises its price target on the AI memory stock. Credo Technology (CRDO) gets a new bull in Evercore ISI after it initiated...
AbbVie to Buy Apogee Therapeutics for $10.9 Billion
Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, ...
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on June 22, 2026, providing details for shareholder voting and corporate governance matters.
Apogee Therapeutics Proxy statement: Proxy filing
Apogee Therapeutics filed a proxy statement on June 22, 2026, providing details for shareholder voting and corporate governance matters.
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company's immunology and inflammation portfolio.
Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.
AbbVie will acquire the clinical-stage biotech's pipeline of candidates for inflammatory and immunological diseases.
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
AbbVie will acquire biotech Apogee Therapeutics for $10.9 billion in cash, they said on Monday, as the company builds its next-generation immunology pipeline.
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases A...
Intel, Micron, SpaceX, Apogee Therapeutics, and More Stocks That Explain Today's Market
Intel and Micron stocks are heading for further records, while SpaceX, Alphabet, and other big tech names decline.
AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
AbbVie is nearing a deal to acquire inflammatory disease drug developer Apogee Therapeutics for about $10.9 billion in cash, the Financial Times reported on Friday, citing people familiar with the m...
Apogee Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Recent data show zumilokibart delivers robust, durable efficacy in atopic dermatitis with fewer doses, supporting phase III trials and expansion into asthma and EoE. Strategic financing ensures commercialization through 2029, while differentiated dosing and efficacy position the pipeline for strong market access and growth.
Apogee Therapeutics Transcript: AGM 2026
The meeting covered board introductions, voting on director elections, auditor ratification, and executive compensation. All proposals passed with sufficient votes, and no shareholder questions were raised.